UCSF

Healthier Capital Founder and Former One Medical CEO Endorses Medeloop Amid Launch of New AI Research Agent

Retrieved on: 
星期一, 五月 6, 2024
UnitedHealth Group, UCSD, EVP, Health, Research, Amazon, ART, Stanford University, UCSF, 1Life Healthcare, Optum, General partnership

Rubin's board appointment is complemented by an investment in Medeloop from Healthier Capital, the venture capital firm he founded to partner with technology-powered healthcare innovators.

Key Points: 
  • Rubin's board appointment is complemented by an investment in Medeloop from Healthier Capital, the venture capital firm he founded to partner with technology-powered healthcare innovators.
  • This announcement aligns with the debut of Medeloop's new AI Research Agent, which the team has named ART.
  • Building on its robust platform, Medeloop has launched ART, an autonomous research agent poised to transform clinical research workflows with minimal human oversight.
  • "We are thrilled to welcome Amir Dan Rubin from Healthier Capital to Medeloop's board of directors," said CEO, Rene Caissie at Medeloop.

NCCN Policy Summit Encourages Conversation and Action on Sexual Health and Fertility Issues Faced by People with Cancer

Retrieved on: 
星期一, 五月 6, 2024
Education, Adolescence, Fertility, City, Research, National LGBT Cancer Network, Doctor of Philosophy, Gynecologic Oncology (journal), Life, ASCO, Cancer, Concurrent estate, Cervical cancer, Virtual, Cancer prevention, NCCN, Fertility preservation, Infertility, National Comprehensive Cancer Network, Oncology, Survivor, JD, Reproductive Sciences, Quality of life, Patient, OBGYN, Gynaecology, Family, MPH, Division, Fox Chase Cancer Center, Human, Assistant professor, Policy, Associate professor, Obstetrics, UCSF, MBA, Birth control

WASHINGTON, May 6, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted an oncology policy summit, today, focused on how sexual and reproductive health can impact people with cancer before, during, and after treatment. Speakers covered a wide range of topics, within the context of gender and sex, intimacy, fertility and reproductive health, treatment side-effects, and the impact of a changing policy landscape in the wake of new laws and judicial decisions.

Key Points: 
  • WASHINGTON, May 6, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted an oncology policy summit, today, focused on how sexual and reproductive health can impact people with cancer before, during, and after treatment.
  • These evidence-based expert consensus recommendations feature best practices for addressing sexual health, fertility, hormone-related symptoms, and many other late and long-term effects from cancer.
  • "It is so important that education about sexual and reproductive health be included into the training of cancer clinicians if these critical health issues are to be addressed in patients' comprehensive cancer care."
  • Two afternoon keynote speakers shared first-hand looks at the issue of reproductive health and fertility preservation for people undergoing cancer care.

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
星期二, 四月 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian

Retrieved on: 
星期二, 四月 23, 2024
Nature Immunology, School, University, Cancer, Biogen, COVID, SAB, Remdesivir, Medical school, Merck & Co., Los Angeles School, Eli Lilly, Amgen, Developmental Biology (journal), Inflammation, STAT3, Molecular biology, Yale University, Research, Lupus, STAT6, Growth, SH2, JAMA, Eli Lilly and Company, UCSF, Patient, Doctor of Pharmacy, Rheumatoid arthritis, Psoriasis, Vasculitis, Morphic, Lilly, Multiple sclerosis, Drug discovery, SAN, Division, Investigational New Drug, Science and nature, Pharmaceutical industry

“We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix. “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development. He has extensive expertise in immunology and has led the advancement and strategic oversight of deep pipelines with more than ten product candidates reaching the clinic during his Lilly tenure. At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6. Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets. Ajay’s deep experience leading a broad discovery and development immunology portfolio – both internally and through strategic partnerships -- is ideally suited to capitalize on the many opportunities at Recludix.”

Key Points: 
  • “We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix.
  • “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development.
  • At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6.
  • Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets.

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

Retrieved on: 
星期一, 四月 15, 2024
FDA, University, Fast Track, Pharmacy, Food and Drug Administration, TLX, NDA, Food, Radiology, MD, ASX, PET, Partnership, Research, Glioma, UCSF, Patient, FET, Radiopharmaceutical, 18F-FET, Diagnosis

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET).

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET).
  • The granted Fast Track designation is for the characterisation of progressive or recurrent glioma using positron emission tomography (PET).
  • Concurrently, Telix is in the final stages of preparing its U.S. New Drug Application (NDA) for TLX101-CDx in this initial indication, in both adult and paediatric patients.
  • This designation enables expedited review and closer consultation with the FDA during the review process.

Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant

Retrieved on: 
星期三, 五月 1, 2024
Other Health, Software, Research, Pharmaceutical, Philanthropy, Oncology, Technology, Foundation, Science, Biotechnology, Other Science, Health, FDA, University, UCSD, BTRC, Regenerative medicine, HGG, University of California, Partnership, Doctor of Philosophy, CIRM, UCSF, Patient, Analysis of variance, SOC, Enterprise, USC, Neuro

Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.

Key Points: 
  • Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.
  • DGM7 has been shown to be associated with increased overall survival with treatment of recurrent HGG, via retrospective analysis.
  • Anova was approached to assist with the development of the product and was instrumental organizing leading neuro-scientists, developing the study plans, securing FDA approval, preparing the CIRM application, and securing the ultimate CIRM award.
  • The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly diagnosed HGG when compared to historical performance.

Clarity Pediatrics Announces Expansion of Virtual Pediatric ADHD Platform and $10M in Funding

Retrieved on: 
星期一, 四月 22, 2024
Managed Care, General Health, Professional Services, Family, Telemedicine, Virtual Medicine, Consumer, Mental Health, Health Technology, Children, Practice Management, Finance, Health, Kaiser Permanente, American Academy, Investment, ARR, Medicaid, ADHD, BPT, Ginger, Pediatrics (journal), UCSF, Stanford University, Patient, Physician, Medicine, City, Allergy, Function (mathematics), Asthma, Growth, Prevalence, Rock Health, Nursing

Clarity Pediatrics , a digital health company reimagining pediatric chronic care, announced today the expansion of their pediatric ADHD platform and $10M in seed funding led by Rethink Impact with participation from Homebrew and Maverick Ventures .

Key Points: 
  • Clarity Pediatrics , a digital health company reimagining pediatric chronic care, announced today the expansion of their pediatric ADHD platform and $10M in seed funding led by Rethink Impact with participation from Homebrew and Maverick Ventures .
  • This investment supports Clarity Pediatrics’ launch of new clinical service lines, further development of their innovative care platform, and geographic expansion.
  • The cornerstone of Clarity Pediatrics’ approach to ADHD care is Behavioral Parent Training (BPT), recommended by the American Academy of Pediatrics for families of children ages 5 to 12 with mild-moderate ADHD.
  • Clarity Pediatrics makes pediatric ADHD care 10x more accessible and 20x more affordable: families have access to next-day appointments, including for ADHD diagnostic screening and medication-related services, and pay an average co-pay of $15 per session.

Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections

Retrieved on: 
星期三, 四月 17, 2024
Research, Infectious Diseases, Neurology, Biotechnology, Other Health, Health, General Health, Other Science, Science, American Academy, GenePeeks, University, Cancer, Foundation Medicine, Genomics, DSM-IV codes, Infection, Bacteria, Fortune 500, Medical laboratory, Clear Labs, NGS, CLIA, Medicine, Encephalitis, UCSF, Ventricular septal defect, Patient, Meningitis, Parasitism, AAN, Physician, Immunodeficiency, Virus, Neuro, Fungus, CSF, Diagnosis, Neoplasm, Cerebrospinal fluid, Metagenomics, Pharmaceutical industry

The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.

Key Points: 
  • The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.
  • In addition, the study found mNGS provided a definitive diagnosis for nearly 1 in 3 immunocompromised patients.
  • Ultimately, Delve Neuro will enable more patients with potentially life-threatening neurological infections to benefit from faster, more comprehensive diagnoses.
  • Prior to joining Delve Bio, Mr. Field served as Chief Commercial Officer at Clear Labs and IDbyDNA (acquired by Illumina).

AMPEL BioSolutions Selected as Member of ARPA-H Customer Experience Hub Spoke Network

Retrieved on: 
星期二, 四月 23, 2024
Mayo Clinic, DARPA, Providence Healthcare, Inflammation, United, Lupus, Capital, Blood, ARPANET, Partnering, Health, Cleveland Clinic, MUSC, Customer experience, Nation, University, Autoimmunity, Disease, Duke, UCSF, ARPA, Gene expression, QuidelOrtho, Mass General Brigham, Clinical trial, Medicine, Biotechnology

CHARLOTTESVILLE, Va., April 23, 2024 /PRNewswire/ -- AMPEL BioSolutions has been selected as a member - or "spoke" - of the Customer Experience Hub of ARPANET-H , a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H) .

Key Points: 
  • CHARLOTTESVILLE, Va., April 23, 2024 /PRNewswire/ -- AMPEL BioSolutions has been selected as a member - or "spoke" - of the Customer Experience Hub of ARPANET-H , a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H) .
  • AMPEL's ARPA-H spoke election highlights one-of-a-kind Precision Health tests that predict inflammation and abnormal drug targets from gene expression utilizing "explainable AI" (xAI).
  • Other corporate Hub Spoke members include Verily, Datavant, Velsara, QuidelOrtho and Biolabs.
  • As a Customer Experience spoke, AMPEL has access to funding and flexible contracting for expeditious product execution and scaling.

Renowned Alzheimer's Neurologist Dale Bredesen, MD, Joins Pacific Neuroscience Institute

Retrieved on: 
星期二, 四月 16, 2024
UCLA, Neurodegenerative disease, Alzheimer's disease, Duke University Hospital, Brain, University, Dementia, Recode, Hope, NIH, Risk, Arrest, University of California, PNI, Doctor of Philosophy, The New York Times, Research, Trial of the century, History, Confusion, Exercise, Documentation, Ageing, UCSF, Buck, Patient, Survivor, Neurology, Medicine, Faculty, Amnesia, Quality of life, Nobel, UC, Nursing

SANTA MONICA, Calif., April 16, 2024 /PRNewswire/ -- Pacific Neuroscience Institute® (PNI) is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®. Over the past four months, as the senior director of the nascent Precision Brain Health program, he and his colleagues have been intensely focused on developing what promises to be the world's first formalized system to comprehensively address neurodegenerative disease in the world. While not quite ready for primetime, the excitement around the clinical implications for patients is palpable.

Key Points: 
  • SANTA MONICA, Calif., April 16, 2024 /PRNewswire/ -- Pacific Neuroscience Institute® (PNI) is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®.
  • Taking a personalized, biological systemwide approach and becoming proactive about interventions, represent the first steps towards stopping Alzheimer's in its tracks."
  • Pacific Neuroscience Institute has a history of innovation that fits perfectly with the development of this novel program."
  • He directed the Program on Aging at the Burnham Institute and joined the Buck Institute as founding president and CEO.